In vitro evidence for the formation of reactive intermediates of resveratrol in human liver microsomes

Xenobiotica

Volumn 40, Issue 1, 2010, Pages 62-71

  Steenwyk, R C ^a   Tan, B ^a  

^a PFIZER INC   (United States)

Author keywords

Human liver microsomes; Piceatannol; Quinone methide; Resveratrol

Indexed keywords

ASCORBIC ACID; CATALASE; DRUG METABOLITE; EPOXIDE HYDROLASE; GLUTATHIONE; PICEATANNOL; PROPANOL QUINONE METHIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESVERATROL; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; OXIDATION; TANDEM MASS SPECTROMETRY;

ANTIOXIDANTS; CATALASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPOXIDE HYDROLASES; FREE RADICAL SCAVENGERS; GLUTATHIONE; HUMANS; INDOLEQUINONES; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STILBENES; SUPEROXIDE DISMUTASE;

EID: 72949111135     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903337384     Document Type: Article

References (20)

1. Baur J, Pearson K, Price N, Jamieson H, Lerin C, Kalra A, Prabhu V, Allard J, Lopez-Lluch G, Lewis K, Pistell P, Poosala S, Becker K, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein K, Spencer R, Lakatta E, Couteur D, Shaw R, Navas P, Puigserver P, Ingram D, de Cabo R, Sinclair, D. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342.
2. Chan W, Delucchi A. (2000). Resveratrol, a red wind constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 76:3103-3112.
3. Dong Z. (2003). Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res 523-4:145-150.
4. Fan P, Zhang F, Bolton J. (2000). 4-Hydroxylated metabolites or the antiestrogens tamoxiphen and toremifine are metabolized to unusually stable quinone methides. Chem Res Toxicol 13:45-52.
5. Gerhauser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knauft J, Liu G, Sitthimonchai S, Frank N. (2003). Mechanism-base in vitro screening of potential cancer chemopreventive agents. Mutat Res 523-4:163-172.
6. Gill M, Bajaj R, Chang C, Nichols D, McLaughlin. (1987). 3,3′OElig;,5′OElig;-Tri-Omethylpiceatannol: Improvement over piceatannol in bioactivity. J Natur Prod 50:36-40.
7. Hebbar V, Shen G, Hu R, Kim B, Chen C, Korytko P, Crowell J, Levine B, Kong T. (2004). Toxicogenomics of resveratrol in rat liver. Life Sci 76:2299-2314.
8. Jang M, Cai L, Udeani G, Slowing K, Thomas C, Beecher C. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220.
9. Marier J, Vachon P, Gritsas A, Zhang J, Moreau J, Ducharme M. (2002). Metabolism and disposition of resveratrol in rats: Extent of absorbtion, glucronidation and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302:369-373.
10. Murias M, Jager W. Handler N, Erker T, Horvath Z, Szekeres T, Hohl H, Gille L. (2004). Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogs: Structure-activity relationship. Biochem Pharmacol 69:903-912.
11. Pervaiz S. (2003). Resveratrol: From grapevines to mammalian biology. FASEB J 17:1975-1985.
12. Piver B, Fer M, Vitrac X, Merillon J, Dreano Y, Berthou F, Lucas D. (2004). Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol 68:773-782.
13. Potter G, Patterson L, Wanogho E, Perry P, Butler P, Ijaz T, Ruparelia K, Lamb J, Farmer P, Stanley L Burke M. (2002). The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enxyme CYP1B1. Br J Cancer 86:774-778.
14. Roupe K, Teng X, Fu Xing, Meadows G, Davies N. (2004). Determination of picattanol in rat serum and liver microsomes: Pharmacokinteics and phase I and phase II bioatransformation. Biomed Chromatogr 18:468-491.
15. Urpi-Sarda M. Jauregui O, Lamuela-Raventos R, Jaeger W, Miksits M, Covas M, Andres-Lacuevea C. (2005). Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography couple with tandem mass spectrometry. Analyt Chem 77:3149-3155.
16. Walle T, Hsieh F, DeLegge M, Oatis J, Walle U. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Distribut 32:1377-1382.
17. Wang D, Jang T, Wu C, Liu W. (2005). Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS. J Chromatogr B 829:97-106.
18. Yu C, Shun YG, Chow A, Li Y, Kosmeder J, Lee YS, Hirschelman W, Pezzuto J, Mehta R, van Breeman R. (2002). Human, rat, and mouse metabolism of resveratrol. Pharmaceut Res 19:1907-1914.
19. Zhu Y, Chiang H, Zhou J, Fuming X, Kissinger P. (2005). In vitro metabolism study of resveratrol and identification and determination of its metabolite piceatannol by LC/EC and LC/MS/MS. Asian J Drug Metab Pharmacokinet 5:49-54.
20. Zhu Y, Chiang H, Zhou J, Kissinger P. (2003). In vitro metabolism study of resveratrol and identification and determination of its metabolite piceatannol by LC/EC and LC/MS/MS. Curr Separat 20:393-396